Retinal toxicity after initial administration of nivolumab and ipilimumab

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: In: Case Reports in Ophthalmological Medicine ; 2023 (2023). - ISSN 2090-6722. - eISSN 2090-6730

Keyword: Netzhautdegeneration
Immun-Checkpoint
Arzneimittelnebenwirkung

Event: Veröffentlichung

(where): Ulm

(who): Universität Ulm

(when): 2023

Creator: Kilani, Adnan
Vounotrypidis, Efstathios
König, Susanna F.
Wolf, Armin

DOI: 10.18725/OPARU-55221

URN: urn:nbn:de:bsz:289-oparu-55296-4

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:38 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Kilani, Adnan
Vounotrypidis, Efstathios
König, Susanna F.
Wolf, Armin
Universität Ulm

Time of origin

2023

Other Objects (12)

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

$Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma$

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Retinal toxicity after initial administration of nivolumab and ipilimumab

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Related objects

Reset password